Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Friday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Organovo stock opened at $0.35 on Friday. Organovo has a fifty-two week low of $0.32 and a fifty-two week high of $1.74. The stock has a market cap of $5.38 million, a P/E ratio of -0.33 and a beta of 0.54. The firm’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.46.

Organovo (NASDAQ:ONVO) last announced its earnings results on Friday, November 8th. The medical research company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.04 million. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. Sell-side analysts predict that Organovo will post -0.77 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.